From this analysis we demonstrate the clinical validity and utility of four immune-linked, high effect size, rare variants for use in an iatrogenic PML risk genetic test in the following genes: C8B, FCN2, STXBP2, and LY9 (Tables 2–5). This evidence concerns the gene STXBP2 and progressive multifocal leukoencephalopathy.